Novo Nordisk announces major expansion of Chartres manufacturing site in France
Novo Nordisk, a global healthcare leader, has announced a significant investment exceeding 16 billion Danish kroner (2.1 billion euros), slated to begin in 2023, to expand its existing production facility in Chartres, France. This strategic investment is aimed at enhancing the site’s capacity to meet the increasing demand for products within serious chronic diseases.
Enhancing Manufacturing Capabilities
The expansion will substantially increase the manufacturing site’s capacity, incorporating aseptic production and finished production processes, along with an extension of the current Quality Control Laboratory. This upgrade, particularly focusing on GLP-1 products, bolsters Novo Nordisk’s capabilities in delivering innovative medicines for the future.
Strategic Importance of the Chartres Site
Lone Charlotte Larsen, corporate vice president of Novo Nordisk Production Chartres, highlighted the strategic significance of the French manufacturing site as a key element in the company’s growth. By utilizing the existing skills and infrastructure, Novo Nordisk aims to expand its capacity efficiently.
Novo Nordisk Invests 16 Billion DKK to Enhance Production Capacity in Chartres, France
Future-Proof and Sustainable Facility Design
The newly designed facility will more than double the site’s footprint, embracing state-of-the-art technology and a multi-product setup to accommodate future processes. The construction will prioritize delivering high-quality products in an environmentally sustainable manner.
Global Investment and Job Creation
Henrik Wulff, executive vice president of Product Supply, Quality & IT at Novo Nordisk, underlined the company’s global investment commitment. The construction projects, commencing now and finalizing between 2026 and 2028, are anticipated to create over 500 new jobs for 24/7 production activities. The construction phase itself will employ up to 2,000 external workers.
Novo Nordisk’s Legacy in Chartres
Established in 1961, the Novo Nordisk facility in Chartres currently employs around 1,600 people and is instrumental in manufacturing high-quality treatments for diabetes, serving millions worldwide.
Novo Nordisk’s investment in the Chartres facility represents a significant commitment to meeting the evolving needs of patients with serious chronic diseases while contributing to the economic and employment growth in the pharmaceutical sector.